The Latin America, Middle East and Africa Infectious Respiratory Disease Diagnostics Market would witness market growth of -2.3% CAGR during the forecast period (2022-2028).
The modern approach of laboratory diagnosis for respiratory viral infections has evolved as molecular testing, which normally offers a quick turnaround time. The majority of respiratory pathogen molecular test findings are accessible in a few hours, with some platforms providing results in as little as one. A single specimen can now be tested for numerous infections because of the development of multiplexed panels from early molecular assays, which were initially created to target a single pathogen.
The respiratory targets selected differ greatly from manufacturer to manufacturer. There are single pathogen assays, mini panels that test a small number of targets, and comprehensive panels that test a large number of pathogens from a single material. Results are accessible considerably more quickly, but the convenience comes at a premium price. The cost of the assay reagents and/or reimbursement for the tests based on clinical presentation and diagnosis could be utilized to account for this.
Acute respiratory tract infections (RTIs) are becoming more common, and this causes significant mortality rates in both children and adults around the world. In the past few years, RTI caused a large number of deaths across all age categories, making it the third greatest cause of mortality worldwide, behind cardiovascular illnesses and neoplasms.
Large portions of the Middle East are desert. While it can be hot and humid in the summer, the temperature can drop significantly in the winter. Invulnerable people, especially asthmatics, may experience an aggravation of chronic lung diseases as a result of these weather changes. Although the prevalence of asthma in this region of the world has not been extensively described, it is thought to be high. As a result, the demand for infectious respiratory disease diagnostics would increase.
The Brazil market dominated the LAMEA Infectious Respiratory Disease Diagnostics Market by Country in 2021; thereby, achieving a market value of $719 million by 2028. The Argentina is poised to grow at a CAGR of -1.7% during (2022 - 2028). Additionally, The UAE market would experience a CAGR of -2.5% during (2022 - 2028).
Based on Product Type, the market is segmented into Consumables, Instruments (Imaging Tests, Respiratory Measurement Devices, and Others), Services. Based on Application, the market is segmented into SARS/COVID 19, Influenza, RSV (Respiratory Syncytial Virus), Tuberculosis, Streptococcus Testing, and Others. Based on Sample Type, the market is segmented into Saliva, Anterior Nasal Region, Blood, Nasopharyngeal Swabs (NPS), and Others. Based on Technology, the market is segmented into Molecular Diagnostics, Microbiology, Immunoassay, and Others. Based on End-use, the market is segmented into Diagnostic Laboratories, Hospitals, and Physician Offices & Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Infectious Respiratory Disease Diagnostics Market is Predict to reach $ 37.2 Billion by 2028, at a CAGR of -5.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific, Inc., Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Qiagen N.V., Bio-Rad Laboratories, Inc., Danaher Corporation, Quidel Corporation
By Product Type
By Application
By Sample Type
By Technology
By End Use
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 